Phase 3Recruiting
Everolimus bAsed caLcineurin inhibiTor frEe immunosuppRession oNe Year AfTer lIver transplantatiON (ALTERNATION)
Everolimus bAsed caLcineurin inhibiTor frEe immunosuppRession oNe Year AfTer lIver transplantatiON (ALTERNATION) - a Randomized, Prospective, Multicenter, Open-label, Controlled Phase III Trial
- Sponsor
- Hannover Medical School (Academic or other)
- Enrolment
- 150 planned
- Conditions
- Liver Allograft; Liver Diseases; Liver Transplantation
- Interventions
- Everolimus; Tacrolimus or Cyclosporine
- Ages
- adults, older adults
- Registry
- NCT07739914
From the registry
The overall aim of this study is nephroprotection based on a calcineurin inhibitor (CNI)-free therapy beyond year one after orthotopic liver transplantation (OLT) in highly pre-selected patients with low rejection risk.
Primary outcomes
- Change from baseline to 14 months in the eGFR between CNI-free and SOC group